BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 19352566)

  • 1. Diabetic patients with normal baseline renal function are at increased risk of developing contrast-induced nephropathy post-percutaneous coronary intervention.
    Chong E; Poh KK; Shen L; Chai P; Tan HC
    Singapore Med J; 2009 Mar; 50(3):250-4. PubMed ID: 19352566
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Contrast nephropathy in high-risk patients undergoing coronary angiography and intervention.
    Uddin MA; Rabbani MA; Jafary FH; Bhatti MA; Islam M
    J Coll Physicians Surg Pak; 2005 Dec; 15(12):791-4. PubMed ID: 16398973
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk stratification according to the type of impaired renal function in patients with acute myocardial infarction treated with percutaneous coronary intervention.
    Kowalczyk J; Lenarczyk R; Kowalski O; Swiatkowski A; Stabryła-Deska J; Kurek T; Honisz G; Kukulski T; Gasior M; Kalarus Z
    Kardiol Pol; 2007 Jun; 65(6):635-43; discussion 644. PubMed ID: 17629825
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of contrast-induced nephropathy in diabetic patients undergoing elective cardiac catheterization or PCI: role of volume-to-creatinine clearance ratio and iodine dose-to-creatinine clearance ratio.
    Worasuwannarak S; Pornratanarangsi S
    J Med Assoc Thai; 2010 Jan; 93 Suppl 1():S29-34. PubMed ID: 20364554
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of NaCl saline hydration and N-Acetyl Cysteine to prevent contrast induced nephropathy in different populations of patients at high and low risk undergoing coronary artery angiography.
    Calabrò P; Bianchi R; Caprile M; Sordelli C; Cappelli Bigazzi M; Palmieri R; Gigantino G; Limongelli G; Capozzi G; Cuomo S; Calabrò R
    Minerva Cardioangiol; 2010 Feb; 58(1):35-40. PubMed ID: 20145594
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of contrast-induced nephropathy in diabetics undergoing elective percutaneous coronary intervention: role of the ratio of contrast medium volume to estimated glomerular filtration rate.
    Wang XC; Fu XH; Wang YB; Jia XW; Wu WL; Gu XS; Zhang J; Su JL; Hao GZ; Jiang YF; Fan WZ; Li SQ
    Chin Med J (Engl); 2011 Mar; 124(6):892-6. PubMed ID: 21518598
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Contrast-induced nephropathy in patients undergoing primary angioplasty for acute myocardial infarction.
    Marenzi G; Lauri G; Assanelli E; Campodonico J; De Metrio M; Marana I; Grazi M; Veglia F; Bartorelli AL
    J Am Coll Cardiol; 2004 Nov; 44(9):1780-5. PubMed ID: 15519007
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of gender on the incidence and outcome of contrast-induced nephropathy after percutaneous coronary intervention.
    Iakovou I; Dangas G; Mehran R; Lansky AJ; Ashby DT; Fahy M; Mintz GS; Kent KM; Pichard AD; Satler LF; Stone GW; Leon MB
    J Invasive Cardiol; 2003 Jan; 15(1):18-22. PubMed ID: 12499523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acetylcysteine In Diabetes (AID): a randomized study of acetylcysteine for the prevention of contrast nephropathy in diabetics.
    Coyle LC; Rodriguez A; Jeschke RE; Simon-Lee A; Abbott KC; Taylor AJ
    Am Heart J; 2006 May; 151(5):1032.e9-12. PubMed ID: 16644332
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence, predictors, and outcomes of post-percutaneous coronary intervention nephropathy in patients with diabetes mellitus and normal baseline serum creatinine levels.
    Roy P; Raya V; Okabe T; Pinto Slottow TL; Steinberg DH; Smith K; Xue Z; Satler LF; Kent KM; Suddath WO; Pichard AD; Lindsay J; Waksman R
    Am J Cardiol; 2008 Jun; 101(11):1544-9. PubMed ID: 18489931
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Statins for prevention of contrast-induced nephropathy in patients undergoing non-emergent percutaneous coronary intervention.
    Kandula P; Shah R; Singh N; Markwell SJ; Bhensdadia N; Navaneethan SD
    Nephrology (Carlton); 2010 Mar; 15(2):165-70. PubMed ID: 20470274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. B-type natriuretic peptide for prevention of contrast-induced nephropathy in patients with heart failure undergoing primary percutaneous coronary intervention.
    Zhang J; Fu X; Jia X; Fan X; Gu X; Li S; Wu W; Fan W; Su J; Hao G; Jiang Y; Xue L
    Acta Radiol; 2010 Jul; 51(6):641-8. PubMed ID: 20438292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sodium bicarbonate, N-acetylcysteine, and saline for prevention of radiocontrast-induced nephropathy. A comparison of 3 regimens for protecting contrast-induced nephropathy in patients undergoing coronary procedures. A single-center prospective controlled trial.
    Ozcan EE; Guneri S; Akdeniz B; Akyildiz IZ; Senaslan O; Baris N; Aslan O; Badak O
    Am Heart J; 2007 Sep; 154(3):539-44. PubMed ID: 17719303
    [TBL] [Abstract][Full Text] [Related]  

  • 14. N-acetylcysteine and contrast-induced nephropathy in primary angioplasty.
    Marenzi G; Assanelli E; Marana I; Lauri G; Campodonico J; Grazi M; De Metrio M; Galli S; Fabbiocchi F; Montorsi P; Veglia F; Bartorelli AL
    N Engl J Med; 2006 Jun; 354(26):2773-82. PubMed ID: 16807414
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized trial of saline hydration to prevent contrast-induced nephropathy in patients on regular captopril or furosemide therapy undergoing percutaneous coronary intervention.
    Shemirani H; Pourrmoghaddas M
    Saudi J Kidney Dis Transpl; 2012 Mar; 23(2):280-5. PubMed ID: 22382219
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frequency and predictors of contrast-induced nephropathy after angioplasty for chronic total occlusions.
    Aguiar-Souto P; Ferrante G; Del Furia F; Barlis P; Khurana R; Di Mario C
    Int J Cardiol; 2010 Feb; 139(1):68-74. PubMed ID: 19056138
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contrast-induced nephrotoxicity in renal allograft recipients.
    Ahuja TS; Niaz N; Agraharkar M
    Clin Nephrol; 2000 Jul; 54(1):11-4. PubMed ID: 10939751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Statin therapy reduces contrast-induced nephropathy: an analysis of contemporary percutaneous interventions.
    Khanal S; Attallah N; Smith DE; Kline-Rogers E; Share D; O'Donnell MJ; Moscucci M
    Am J Med; 2005 Aug; 118(8):843-9. PubMed ID: 16084176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of N-acetylcysteine and aminophylline in preventing contrast-induced nephropathy.
    Kinbara T; Hayano T; Ohtani N; Furutani Y; Moritani K; Matsuzaki M
    J Cardiol; 2010 Mar; 55(2):174-9. PubMed ID: 20206069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of anisodamine on prevention of contrast induced nephropathy in patients with acute coronary syndrome.
    Wang YB; Fu XH; Gu XS; Wang XC; Zhao YJ; Hao GZ; Jiang YF; Fan WZ; Wu WL; Li SQ; Xue L
    Chin Med J (Engl); 2012 Mar; 125(6):1063-7. PubMed ID: 22613532
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.